about
Global Changes in Food Supply and the Obesity Epidemic.Urinary alpha- and pi-glutathione s-transferases in adult patients with type 1 diabetesAdditive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes.Impaired coronary microcirculation in type 2 diabetic patients is associated with elevated circulating regulatory T cells and reduced number of IL-21R⁺ T cells.Aetiological factors behind adipose tissue inflammation: an unexplored research area.Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes.The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication.Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria.Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria.Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.The effect of liraglutide on renal function: A randomized clinical trial.High osteoprotegerin is associated with development of foot ulcer in type 1 diabetes.Cardiac (82)Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes.Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment.Cardiac Autonomic Function Is Associated With the Coronary Microcirculatory Function in Patients With Type 2 DiabetesAbnormal echocardiography in patients with type 2 diabetes and relation to symptoms and clinical characteristicsTime course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatmentSafety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease
P50
Q30244927-64BF9F39-674A-473C-A09B-D51E3F1A2316Q34181053-51DF1EC4-B644-4473-B8CA-1D6F0A700A82Q35810520-93D620EF-49F1-4165-8B6E-9BA38F6F85EDQ36815448-D7AF0C5D-78EF-43DB-9A60-984DD63E2592Q37998610-D71709B9-13B4-4FD4-840E-0C2C92B2DE57Q38412125-09C11912-5862-4747-BA04-52717A001599Q40567052-F8BDD419-C83B-4ACD-BC74-4A04B09BA362Q40823785-BD4B0FCA-BFE6-4216-9390-DE7FE52546CDQ41064007-E0BD45B9-3BA3-41A3-984F-17A36C5B7912Q48331707-CF85DD5E-8292-4051-BF1D-D50BE58CCBBDQ51381510-682F4D7B-EE70-4446-AC27-FA8B68AFEECAQ51609466-3EEACEB7-7228-4A5B-BADA-C44FA60B6123Q52989347-AE263296-BC0E-4BE6-AB41-5A55D3B02B30Q53765220-015E6BE1-FB1F-462E-A570-C6C434EC7BF8Q57680256-927366AA-36E8-4541-A5BB-51D5ECD4D12FQ61948351-DCBDDC89-9854-4FA6-95E7-9252F85E660DQ61948354-7094AB73-731D-4C20-A765-8DE21A581A29Q90051116-44499C9F-61D3-49F5-8E4E-3900C78BC813
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Bernt J von Scholten
@ast
Bernt J von Scholten
@en
Bernt J von Scholten
@es
Bernt J von Scholten
@nl
Bernt J von Scholten
@sl
type
label
Bernt J von Scholten
@ast
Bernt J von Scholten
@en
Bernt J von Scholten
@es
Bernt J von Scholten
@nl
Bernt J von Scholten
@sl
prefLabel
Bernt J von Scholten
@ast
Bernt J von Scholten
@en
Bernt J von Scholten
@es
Bernt J von Scholten
@nl
Bernt J von Scholten
@sl
P106
P1153
55776817100
P21
P31
P496
0000-0002-1489-0636